Sponsored Links 
Depomed Poised for a Run
Depomed, Inc. (DEPO - Analyst Report) has risen more than 32% in the last three months to trade near its 52-week high of $4.52. Its deal with CVS Caremark (CVS - Analyst Report) can help in expanding distribution of diabetes drug Glumzeta. The Zacks #1 (Strong Buy) company already has two successful drugs in the market, and looks attractive to shareholders at its current price. Analysts expect a loss of $0.50 per share in 2008, less than their prior forecast of $0.89.
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Free Stock Analysis From Zacks
Includes Zacks Long-Term Recommendation and Target Price
Loading Stories...Related Content
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
0.00 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Feb 10, 2010 05:21 am ET |
150.25
[CLICK TO CLOSE X]